BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as President and Chief Executive Officer.

Third Quarter 2018 Summary

Ophthotech Corporation announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018.

“Food as Health” is New York State’s 1st hospital-based program of its kind

Consolidated Results of Operations, As Reported and As Adjusted - Three-month periods ended June 30, 2018 and 2017

Valent BioSciences Corporation (VBC) officially opened the doors of its new global research facility, the Biorational Research Center (BRC), at a July 24th gala at Libertyville’s stylish Innovation Park.

Seres Therapeutics, Inc. announced that management will host a conference call and live audio webcast on August 2, 2018 at 8:30 a.m. ET to discuss second quarter 2018 financial results and provide a general business update.

This spring, Russell Swan, MD led a team of surgeons from Vance Thompson Vision and the University of Iowa, plus staff members, on a mission trip to Honduras.

BioArctic AB announced on July 6 the positive topline results from the clinical Phase 2b study with BAN2401 in 856 patients with early Alzheimer’s disease.

Liquidia Technologies, Inc. (the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced the pricing of its initial public offering of 4,545,455 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions, for gross proceeds of $50.0 million.